The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Rituximab-Associated Progressive Multifocal Leukoencephalopathy in Rheumatoid Arthritis
Open accessAbstract
Objective: To describe the development of progressive multifocal leukoencephalopathy (PML) in patients with rheumatoid arthritis (RA) treated with rituximab. Design: Case study. Setting: Clinical care for patients with rheumatologic diseases. Most were referred to academic centers for care after diagnosis (Washington University, St Louis, Missouri; Karolinska Insitute, Stockholm, Sweden; and Royal Melbourne Hospital, Melbourne, Australia) while one was cared for in a neurology practice in Dallas, Texas, with consultation by an academic neurovirologist from the University of Colorado in Denver. Patients: Four patients developing PML in the setting of rituximab therapy for RA. Intervention: Rituximab therapy. Main Outcome Measures: Clinical and pathological observations. Results: Four patients from an estimated population of 129 000 exposed to rituximab therapy for RA are reported in whom PML developed after administration of this drug. All were women older than 50 years, commonly with Sjögren syndrome and a history of treatment for joint disease ranging from 3 to 14 years. One case had no prior biologic and minimal immunosuppressive therapy. Progressive multifocal leukoencephalopathy presented as a progressive neurological disorder, with diagnosis confirmed by detection of JC virus DNA in the cerebrospinal fluid or brain biopsy specimen. Two patients died in less than 1 year from PML diagnosis, while 2 remain alive after treatment withdrawal. Magnetic resonance scans and tissue evaluation confirmed the frequent development of inflammatory PML during the course of the disease. Conclusion: These cases suggest an increased risk, about 1 case per 25 000 individuals, of PML in patients with RA being treated with rituximab. Inflammatory PML may occur in this setting even while CD20 counts remain low.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kleinschmidt-DeMasters, B. K., & Tyler, K. L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051782 · Cited by 1,072
Self-citationProgressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's Disease
Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., & Rutgeerts, P. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051586 · Cited by 1,060
Progressive Multifocal Leukoencephalopathy in a Patient Treated with Natalizumab
Langer-Gould, A., Atlas, S. W., Green, A. J., Bollen, A. W., & Pelletier, D. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051847 · Cited by 1,034
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
Yousry, T. A., Major, E. O., Ryschkewitsch, C., Fahle, G., Fischer, S., Hou, J., Curfman, B., Miszkiel, K., Mueller-Lenke, N., Sanchez, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054693 · Cited by 790
Self-citationTan, C. S., & Koralnik, I. J. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70040-5 · Cited by 776
Clifford, D. B., DeLuca, A., Simpson, D. M., Arendt, G., Giovannoni, G., & Nath, A. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70028-4 · Cited by 636
Self-citationMajor, E. O., Amemiya, K., Tornatore, C. S., Houff, S. A., & Berger, J. R. (1992) · Clinical Microbiology Reviews · doi:10.1128/cmr.5.1.49 · Cited by 535
Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., & Bennett, C. L. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70161-5 · Cited by 447
Anti‐JC virus antibodies: Implications for PML Risk Stratification
Gorelik, L., Lerner, M., Bixler, S., Crossman, M., Schlain, B., Simon, K., Pace, A., Cheung, A., Chen, L. L., Berman, M., et al. (2010) · Annals of Neurology · doi:10.1002/ana.22128 · Cited by 433
Hall, C. D., Dafni, U., Simpson, D., Clifford, D., Wetherill, P. E., Cohen, B., McArthur, J., Hollander, H., Yainnoutsos, C., Major, E., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805073381903 · Cited by 346
Self-citationEffect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function
Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J.-C., Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., et al. (2009) · Neurology · doi:10.1212/01.wnl.0000341766.59028.9d · Cited by 282
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name?
Koralnik, I. J. (2006) · Annals of Neurology · doi:10.1002/ana.20933 · Cited by 243
Progressive multifocal leukoencephalopathy in HIV-1 infection
Cinque, P., Koralnik, I. J., Gerevini, S., Miro, J. M., & Price, R. W. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70226-9 · Cited by 213
De Luca, A., Ammassari, A., Pezzotti, P., Cinque, P., Gasnault, J., Berenguer, J., Di Giambenedetto, S., Cingolani, A., Taoufik, Y., Miralles, P., et al. (2008) · AIDS · doi:10.1097/qad.0b013e32830a5043 · Cited by 173
Determinants of survival in progressive multifocal leukoencephalopathy
Marzocchetti, A., Tompkins, T., Clifford, D. B., Gandhi, R. T., Kesari, S., Berger, J. R., Simpson, D. M., Prosperi, M., De Luca, A., & Koralnik, I. J. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c0d4a1 · Cited by 169
Self-citationMolloy, E. S., & Calabrese, L. H. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.07.006 · Cited by 127
Fleischmann, R. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24906 · Cited by 112
Ryschkewitsch, C. F., Jensen, P. N., Monaco, M. C., & Major, E. O. (2010) · Annals of Neurology · doi:10.1002/ana.22137 · Cited by 80
Progressive Multifocal Leukoencephalopathy, Efalizumab, and Immunosuppression
Korman, B. D., Tyler, K. L., & Korman, N. J. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.175 · Cited by 76
Self-citationLima, M. A., Marzocchetti, A., Autissier, P., Tompkins, T., Chen, Y., Gordon, J., Clifford, D. B., Gandhi, R. T., Venna, N., Berger, J. R., et al. (2007) · Journal of Virology · doi:10.1128/jvi.01809-06 · Cited by 58
Self-citation
Cited by
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
Salzer, J., Svenningsson, R., Alping, P., Novakova, L., Björck, A., Fink, K., Islam-Jakobsson, P., Malmeström, C., Axelsson, M., Vågberg, M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003331 · Cited by 354
Mealy, M. A., Wingerchuk, D. M., Palace, J., Greenberg, B. M., & Levy, M. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2013.5699 · Cited by 302
Rigby, M. R., Harris, K. M., Pinckney, A., DiMeglio, L. A., Rendell, M. S., Felner, E. I., Dostou, J. M., Gitelman, S. E., Griffin, K. J., Tsalikian, E., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81722 · Cited by 291
Metadata
- Authors
- Clifford, D. B., Ances, B., Costello, C., Rosen-Schmidt, S., Andersson, M., Parks, D., Perry, A., Yerra, R., Schmidt, R., Alvarez, E., & Tyler, K. L.
- Venue
- Archives of Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2011-09-01
- Volume
- 68
- Issue
- 9
- Pages
- 1156
- ISSN
- 0003-9942 (ISSN-L)
- OpenAlex
- W2114360739
- Cited by
- 278
- References
- 21
- FWCI
- 11.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.